Introduction
Myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal diseases affecting bone marrow and peripheral blood cells resulting from malignant transformation of bone marrow stem cells. 1 MDS have been diagnosed based on cytomorphologic assessment of bone marrow and peripheral blood together with cytochemistry and cytogenetics and classified according to FAB and WHO criteria. [2] [3] [4] Since current classification schemes are heavily weighted on cytomorphologic findings with some patients presenting only with minimal dysplasia not sufficient for a definitive diagnosis of MDS 5 and the presence of karyotype abnormalities in only half of the patients 6 additional diagnostic approaches are needed to adequately diagnose or rule out MDS in patients with peripheral blood cytopenias of unknown cause.
Multiparameter flow cytometry (MFC) is increasingly considered an important additive tool in the diagnostic workup of patients with suspected MDS. 5 It has been demonstrated capable of detecting aberrant antigen expression related to MDS in a variety of studies. [7] [8] [9] [10] Cooperative efforts are made on a multicentric basis to standardize and validate flow cytometric procedures in order to establish MFC as a diagnostic standard for MDS. 11 In addition to the diagnostic value of MFC this method may provide independent prognostic information as has been demonstrated both during conventional or supportive therapy 9;10 as well as following allogeneic stem cell transplantation. 8 A major task in the evaluation of MFC as a diagnostic tool for MDS remains, however, the proper determination of its sensitivity and specificity given that published studies consistently The present analysis therefore was performed in order to determine the significance of flow cytometric findings in agreement with MDS in the absence of a clear-cut cytomorphologic diagnosis of MDS based on patients with suspected MDS serially analyzed in parallel by cytomorphology, MFC and cytogenetics and in part also by moleculargenetics.
Design and Methods

Patients
Patients analyzed at MLL Munich Leukemia Laboratory during the period from August 2005
to July 2011 for suspected MDS were identified in whom bone marrow cytomorphology (CM)
did not unequivocally reveal MDS. The median age of the patients was 68 years (range, 18
to 87 years), 87 were male and 55 female (ratio male:female 1.58). The median (range) of WBC count was 4.2 x10 9 /L (0.9 to 21.7 x10 9 /L), of hemoglobin level 118 g/L (46 to 163 g/L), and of thrombocyte count 109 x10 9 /L (6 to 704 x10 9 /L). Four patients had received prior chemotherapy for pre-existing malignancies. None of the patients had received therapy for MDS before either first or follow-up diagnostic evaluation. Out of these, cases were selected in which multiparameter flow cytometry (MFC) and cytogenetics (CG) were performed in addition and in parallel to CM and for which at least one additional evaluation during followup with CM and MFC in parallel was available. A total of 142 such patients were identified.
CM and MFC analyses were performed independently of each other in each case. In a subset of 38 out of these patients molecular genetic analyses have been performed in addition.
Suspicion of MDS was raised by the physician sending the sample and was based on peripheral blood counts and differential as well as clinical criteria. Cases with hematologic malignancies other than MDS were excluded after the respective diagnosis was confirmed.
Thus, in the present cohort all cases had in common an initial suspicion of MDS. The median number of assessments amounted to 2 per patient (range 2-6). The median interval between first and last assessment amounted to 9 months (range 1-53). cases with cytomorphologic confirmation of MDS at first assessment were not included and patients had to be diagnostically assessed for at least two times. The end point of the present study has been the relation of MFC findings at first assessment to the findings be CM, CG and molecular genetics at follow-up assessment rather than the comparison of all methods at the first assessment.
All patients had given informed consent for the diagnostic analyses and for further workup and research procedures. The study was performed in concordance to the Declaration of Helsinki and was approved by the IRB of the MLL Munich Leukemia Laboratory.
Cytomorphology, cytogenetics, molecular genetics
Cytomorphologic assessment was based on May-Grünwald-Giemsa stains, myeloperoxidase reaction, non-specific esterase using alpha-naphtyl-acetate and iron staining 12 
Multiparameter flow cytometry
MFC was performed and evaluated as described previously 10 applying five-fold-stainings and using the antibodies outlined in table 1 for the analysis of bone marrow samples. Antibodies were purchased from Immunotech (Marseilles, France) except for CD66c (Becton Dickinson, Heidelberg, Germany). Antibody combinations were added to 10 6 cells (volume, 100 µl) and incubated for ten minutes. After addition of 2 ml ammonium chloride-based erythrocyte lysing solution samples were incubated for additional ten minutes and then washed twice in phosphate-buffered saline (PBS) and resuspended in 0.5 ml PBS. FC500 and Navios flow cytometers were used (Beckman Coulter, Miami, FL), 50,000 events were acquired.
Cytomics CXP and Navios software packages (Beckman Coulter) were used for data analysis.
Criteria for rating MFC findings as MDS
Based on a previous study 10 Myeloid blasts: percentage of BM myeloid blasts, coexpression of CD11b, CD5, CD56, CD7, CD15, and CD64 negativity, HLA-DR negativity.
Erythroid cells: homogeneously strong CD71 expression, CD71 negativity.
Statistics
Dichotomous variables were compared using χ 2 -test and Fisher´s exact test and continuous variables by Student´s T-test. All calculations were performed using SPSS 14.0.1 (IBM Corporation, Armonk, NY). p-values reported are two-sided. Out of the ten patients with possible MDS by MFC at initial assessment, who were confirmed MDS by non-MFC methods during follow-up assessments, the MFC result at follow-up assessment turned to MDS in four patients and still was possible MDS in five patients. In one patient no MDS was found by MFC.
Results
Diagnostic results at first assessment
Time to confirmation of MDS
The interval between initial assessment and confirmation of MDS by a non-MFC method was as compared to cases with no MDS by MFC at initial assessment (median 15.6 months, range 7.9-44.4, n.s.).
Discussion
The diagnostic criteria for MDS have been clearly defined in the WHO classification 25 and are based on cytomorphology in addition with cytochemistry and cytogenetics. Nonetheless, there remain a significant number of patients with cytopenias and suspected MDS in whom bone marrow evaluation reveals limited dysplastic features not sufficient to diagnose MDS based on WHO criteria. In general, it is recommended to perform repeat evaluations in these patients in order to document an increase in dysplastic features or blasts sufficient to diagnose MDS or to identify a non-MDS cause for the cytopenia which was not evident at the initial evaluation. 5 Given the increased incidence of MDS observed during recent years as well as an additional significant number of patient with potentially underdiagnosed MDS on the one hand, 26 and given the increase in therapeutic capabilities gained beyond supportive approaches and allogeneic transplantation procedures [27] [28] [29] on the other hand, there is a clear need for improvement in diagnostic procedures in patients in whom at present MDS is diagnosed only during follow-up evaluations.
The flow cytometric assessment of aberrant antigen expression related to MDS is increasingly used in the diagnostic setting of MDS as various studies have shown its diagnostic and even prognostic power. [7] [8] [9] [10] A still unsettled issue, however, is the diagnostic finding of MDS by MFC in the absence of a diagnosis of MDS by standard procedures, i.e. by CM and CG. This has been found to occur in virtually all of the before mentioned studies [7] [8] [9] [10] in a subset of patients and a priori has been discussed as incomplete specificity of MFC in diagnosing MDS. Taking into consideration MDS-specific cytogenetic aberrancies found in part of these patients 10 it becomes clear that MDS may be present and detected by MFC in the absence of dysplastic features by CM.
In the present study we aimed at further clarifying the significance of MFC findings resulting in the diagnosis MDS but in the absence of MDS confirmation by CM. In a series of 142 patients with suspected MDS nine patients (6.3%) were found to carry cytogenetic aberrancies and thereby were confirmed MDS in the absence of a MDS diagnosis by CM at the initial assessment. Furthermore, our present data confirms earlier observations 10 to the findings at initial assessment there were some cases still not diagnosed MDS by CM at follow-up assessments in whom the acquisition of karyotype abnormalities were found leading to confirmation of MDS. In addition, in single cases of those analyzed mutations were found by molecular genetics at follow-up assessment. Since these analyses were performed in a small subset of the present series only, it is not possible to judge on the real frequency of these findings since presumably additional cases molecular mutations would have been identified if the complete cohort would have been analyzed in this regard. Taking into account additional mutations that have been reported on recently, [31] [32] [33] [34] however, it is anticipated that molecular genetic analyses will significantly gain importance in the diagnostic work-up of patients with suspected MDS.
We here report for the first time follow-up assessments in MDS by MFC accompanied by other diagnostic techniques and thereby differ from previous reports on the analysis of MFC as a diagnostic tool for MDS. All other studies published so far found large agreements between diagnostic results of MFC and CM while in subsets of analysed cases discordant diagnostic results occurred which could not be clarified by repeat evaluations at follow-up.
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The present data therefore strongly supports the recommendation to repeat the evaluation of patients with suspected but not confirmed MDS. 5 Taking into account the interval between initial assessment and confirmation of MDS amounting to a median of less than one year in cases with a finding of MDS by only MFC at initial assessment the recommended repeat evaluations should be confirmed at smaller intervals, e.g. after six to nine months periods, if clinical symptoms still make the diagnosis of MDS most probable.
In conclusion, the data of the present study indicates that the evaluation by MFC for aberrant 
